Description of multiple myeloma cases and assessment of survival and mortality factors in Madagascar
ABSTRACTIntroduction In Madagascar, the epidemiologic, therapeutic, and evolutionary aspects of multiple myeloma remain poorly understood. Our objectives were to describe the cases, report factors associated with mortality, and estimate patient survival.Patients and method This was a retrospective d...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Hematology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2023.2261803 |
| _version_ | 1797674749033185280 |
|---|---|
| author | Rova Malala Fandresena Randrianarisoa Valéry Refeno Ny Ony Tiana Florence Andrianandrasana Fidiarivony Ralison Hanta Marie Danielle Vololontiana Florine Rafaramino |
| author_facet | Rova Malala Fandresena Randrianarisoa Valéry Refeno Ny Ony Tiana Florence Andrianandrasana Fidiarivony Ralison Hanta Marie Danielle Vololontiana Florine Rafaramino |
| author_sort | Rova Malala Fandresena Randrianarisoa |
| collection | DOAJ |
| description | ABSTRACTIntroduction In Madagascar, the epidemiologic, therapeutic, and evolutionary aspects of multiple myeloma remain poorly understood. Our objectives were to describe the cases, report factors associated with mortality, and estimate patient survival.Patients and method This was a retrospective descriptive and analytical study conducted in five teaching hospitals in Madagascar: HJRA and CENHOSOA (Antananarivo), CHUPZAGA (Mahajanga), CHUAT (Toamasina) and CHUT (Fianarantsoa). The study included patients diagnosed with multiple myeloma between January 1, 2010 and December 31, 2021.Results Of the 11,374 cancer patients, 75 (0.66%) had multiple myeloma. The mean age of the patients was 59.9 years (±8.9) and the sex ratio was 1.5. Arterial hypertension was observed in 32% of the patients. The most common symptom of myeloma was bone pain (n = 48; 64%). Forty-six patients (61%) were diagnosed with stage III myeloma and 28 patients (37.3%) with stage IIIA myeloma according to the Durie-Salmon classification. Anemia, renal failure, hypercalcemia and fractures were present in 53%, 37%, 21% and 28% of cases, respectively. Fifty-four patients received specific treatment. The combination of melphalan-prednisone-thalidomide was used in 79.63% of cases, and one patient had received autologous stem cell transplantation. Eleven patients (14.67%) died. Chronic kidney disease (p = 0.009), smoking (p = 0.028) and two associated comorbidities (p = 0.035) were associated with mortality. The median overall survival was 45.5 months.Conclusion Patient survival is shorter than reported in the literature. The high mortality rate is due to comorbidities and limited access to recommended therapies. |
| first_indexed | 2024-03-11T22:04:39Z |
| format | Article |
| id | doaj.art-36f11407ad244a7fbbe5e9c3db0f3e42 |
| institution | Directory Open Access Journal |
| issn | 1607-8454 |
| language | English |
| last_indexed | 2024-03-11T22:04:39Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Hematology |
| spelling | doaj.art-36f11407ad244a7fbbe5e9c3db0f3e422023-09-25T09:14:54ZengTaylor & Francis GroupHematology1607-84542023-12-0128110.1080/16078454.2023.2261803Description of multiple myeloma cases and assessment of survival and mortality factors in MadagascarRova Malala Fandresena Randrianarisoa0Valéry Refeno1Ny Ony Tiana Florence Andrianandrasana2Fidiarivony Ralison3Hanta Marie Danielle Vololontiana4Florine Rafaramino5Department of Internal Medicine, Joseph Raseta Befelatanana Hospital, Antananarivo, MadagascarOncology Department, Professeur Zafisaona Gabriel Hospital, Mahajanga, MadagascarOncology Department, Joseph Ravoahangy Andrianavalona Hospital, Antananarivo, MadagascarDepartment of Internal Medicine, Mahavoky Atsimo Hospital, Mahajanga, MadagascarDepartment of Internal Medicine, Joseph Raseta Befelatanana Hospital, Antananarivo, MadagascarFaculty of Medicine, Antananarivo, MadagascarABSTRACTIntroduction In Madagascar, the epidemiologic, therapeutic, and evolutionary aspects of multiple myeloma remain poorly understood. Our objectives were to describe the cases, report factors associated with mortality, and estimate patient survival.Patients and method This was a retrospective descriptive and analytical study conducted in five teaching hospitals in Madagascar: HJRA and CENHOSOA (Antananarivo), CHUPZAGA (Mahajanga), CHUAT (Toamasina) and CHUT (Fianarantsoa). The study included patients diagnosed with multiple myeloma between January 1, 2010 and December 31, 2021.Results Of the 11,374 cancer patients, 75 (0.66%) had multiple myeloma. The mean age of the patients was 59.9 years (±8.9) and the sex ratio was 1.5. Arterial hypertension was observed in 32% of the patients. The most common symptom of myeloma was bone pain (n = 48; 64%). Forty-six patients (61%) were diagnosed with stage III myeloma and 28 patients (37.3%) with stage IIIA myeloma according to the Durie-Salmon classification. Anemia, renal failure, hypercalcemia and fractures were present in 53%, 37%, 21% and 28% of cases, respectively. Fifty-four patients received specific treatment. The combination of melphalan-prednisone-thalidomide was used in 79.63% of cases, and one patient had received autologous stem cell transplantation. Eleven patients (14.67%) died. Chronic kidney disease (p = 0.009), smoking (p = 0.028) and two associated comorbidities (p = 0.035) were associated with mortality. The median overall survival was 45.5 months.Conclusion Patient survival is shorter than reported in the literature. The high mortality rate is due to comorbidities and limited access to recommended therapies.https://www.tandfonline.com/doi/10.1080/16078454.2023.2261803EpidemiologyMadagascarmortalitymultiple myelomasurvival |
| spellingShingle | Rova Malala Fandresena Randrianarisoa Valéry Refeno Ny Ony Tiana Florence Andrianandrasana Fidiarivony Ralison Hanta Marie Danielle Vololontiana Florine Rafaramino Description of multiple myeloma cases and assessment of survival and mortality factors in Madagascar Hematology Epidemiology Madagascar mortality multiple myeloma survival |
| title | Description of multiple myeloma cases and assessment of survival and mortality factors in Madagascar |
| title_full | Description of multiple myeloma cases and assessment of survival and mortality factors in Madagascar |
| title_fullStr | Description of multiple myeloma cases and assessment of survival and mortality factors in Madagascar |
| title_full_unstemmed | Description of multiple myeloma cases and assessment of survival and mortality factors in Madagascar |
| title_short | Description of multiple myeloma cases and assessment of survival and mortality factors in Madagascar |
| title_sort | description of multiple myeloma cases and assessment of survival and mortality factors in madagascar |
| topic | Epidemiology Madagascar mortality multiple myeloma survival |
| url | https://www.tandfonline.com/doi/10.1080/16078454.2023.2261803 |
| work_keys_str_mv | AT rovamalalafandresenarandrianarisoa descriptionofmultiplemyelomacasesandassessmentofsurvivalandmortalityfactorsinmadagascar AT valeryrefeno descriptionofmultiplemyelomacasesandassessmentofsurvivalandmortalityfactorsinmadagascar AT nyonytianaflorenceandrianandrasana descriptionofmultiplemyelomacasesandassessmentofsurvivalandmortalityfactorsinmadagascar AT fidiarivonyralison descriptionofmultiplemyelomacasesandassessmentofsurvivalandmortalityfactorsinmadagascar AT hantamariedaniellevololontiana descriptionofmultiplemyelomacasesandassessmentofsurvivalandmortalityfactorsinmadagascar AT florinerafaramino descriptionofmultiplemyelomacasesandassessmentofsurvivalandmortalityfactorsinmadagascar |